Cargando…

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice

OBJECTIVE: There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaomei, Qiang, Wei, Liu, Xingjun, Liu, Lianye, Liu, Shu, Gao, Aibo, Gao, Shan, Shi, Bingyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321192/
https://www.ncbi.nlm.nih.gov/pubmed/25468954
http://dx.doi.org/10.1530/EJE-14-0704
_version_ 1782356244198064128
author Liu, Xiaomei
Qiang, Wei
Liu, Xingjun
Liu, Lianye
Liu, Shu
Gao, Aibo
Gao, Shan
Shi, Bingyin
author_facet Liu, Xiaomei
Qiang, Wei
Liu, Xingjun
Liu, Lianye
Liu, Shu
Gao, Aibo
Gao, Shan
Shi, Bingyin
author_sort Liu, Xiaomei
collection PubMed
description OBJECTIVE: There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission. DESIGN: A prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy. METHODS: A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal. RESULTS: Of the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal. CONCLUSION: A second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission.
format Online
Article
Text
id pubmed-4321192
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-43211922015-03-09 A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice Liu, Xiaomei Qiang, Wei Liu, Xingjun Liu, Lianye Liu, Shu Gao, Aibo Gao, Shan Shi, Bingyin Eur J Endocrinol Clinical Study OBJECTIVE: There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission. DESIGN: A prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy. METHODS: A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal. RESULTS: Of the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal. CONCLUSION: A second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission. Bioscientifica Ltd 2015-03 /pmc/articles/PMC4321192/ /pubmed/25468954 http://dx.doi.org/10.1530/EJE-14-0704 Text en © 2015 The authors http://creativecommons.org/licenses/by/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB)
spellingShingle Clinical Study
Liu, Xiaomei
Qiang, Wei
Liu, Xingjun
Liu, Lianye
Liu, Shu
Gao, Aibo
Gao, Shan
Shi, Bingyin
A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title_full A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title_fullStr A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title_full_unstemmed A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title_short A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
title_sort second course of antithyroid drug therapy for recurrent graves' disease: an experience in endocrine practice
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321192/
https://www.ncbi.nlm.nih.gov/pubmed/25468954
http://dx.doi.org/10.1530/EJE-14-0704
work_keys_str_mv AT liuxiaomei asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT qiangwei asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liuxingjun asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liulianye asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liushu asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT gaoaibo asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT gaoshan asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT shibingyin asecondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liuxiaomei secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT qiangwei secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liuxingjun secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liulianye secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT liushu secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT gaoaibo secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT gaoshan secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice
AT shibingyin secondcourseofantithyroiddrugtherapyforrecurrentgravesdiseaseanexperienceinendocrinepractice